MNTA Momenta Pharmaceuticals, Inc.

14.00
+0  (0%)
Previous Close 14.00
Open 13.95
Price To book 2.60
Market Cap 967.16M
Shares 69,083,000
Volume 612,046
Short Ratio 3.09
Av. Daily Volume 824,347

SEC filingsSee all SEC filings

  1. DEF 14A - Other definitive proxy statements 17786330
  2. 8-K - Current report 17697962
  3. 8-K - Current report 17673913
  4. CT ORDER - Confidential treatment order 17662030
  5. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17638130

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial met primary endpoint - November 29, 2016.
M923
Moderate-to-severe chronic plaque psoriasis
Filed 2007. Approved April 16 2015.
Generic Copaxone
Multiple sclerosis
Phase 2 development discontinued due to poor efficacy shown
Necuparanib (MOM-M402-103)
Advanced metastatic pancreatic cancer

Latest News

  1. Momenta Pharmaceuticals to Webcast Presentation at the Deutsche Bank 42nd Annual Health Care Conference
  2. Momenta Pharmaceuticals Announces Date of First Quarter 2017 Financial Results Conference Call and Webcast
  3. Why Is Momenta (MNTA) Down 9.6% Since the Last Earnings Report?
  4. Lifshitz & Miller LLP Announces Investigation of Aratana Therapeutics, Inc., FXCM Inc., Innocoll Holdings plc, Momenta Pharmaceuticals, Inc., Omnicom Group Inc., Perrigo Company plc, Santander Consumer USA Holdings Inc. and The Interpublic Group of Companies, Inc.
  5. INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving the Board of Momenta Pharmaceuticals, Inc. -- MNTA
  6. FDA warns Pfizer over contaminated drugs at Kansas plant
  7. Momenta Pharmaceuticals to Webcast Presentation at the Cowen and Company 37th Annual Health Care Conference
  8. SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Momenta Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm
  9. Glancy Prongay & Murray LLP Commences Investigation on Behalf of Momenta Pharmaceuticals, Inc. Investors
  10. Momenta Pharmaceuticals, Inc. Earnings Take a Back Seat
  11. Clovis (CLVS) Q4 Loss Wider than Expected; Focus on Rubraca
  12. Momenta Tops Q4 Earnings, Shares Down on Warning Letter
  13. IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Momenta Pharmaceuticals, Inc., and Encourages Investors to Contact the Firm
  14. Manufacturing Delay Of Generic Drug From Pfizer Inc. (PFE) A Relief For Teva Pharmaceutical Industries Ltd (ADR) (TEVA)
  15. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving the Board of Momenta Pharmaceuticals, Inc. -- MNTA
  16. Momenta 4Q Net 60 Cents a Share
  17. INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Momenta Pharmaceuticals, Inc. Investors
  18. Momenta Pharmaceuticals, Inc. :MNTA-US: Earnings Analysis: Q4, 2016 By the Numbers : February 22, 2017
  19. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Momenta Pharmaceuticals, Inc. (MNTA)